1
|
Graham G. Disparities in cardiovascular disease risk in the United States. Curr Cardiol Rev 2015; 11:238-45. [PMID: 25418513 PMCID: PMC4558355 DOI: 10.2174/1573403x11666141122220003] [Citation(s) in RCA: 257] [Impact Index Per Article: 28.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/17/2014] [Revised: 11/10/2014] [Accepted: 11/12/2014] [Indexed: 12/25/2022] Open
Abstract
This is a comprehensive narrative review of the literature on the current science and evidence of population-level differences in risk factors for heart disease among different racial and ethnic population in the United States (U.S.). It begins by discussing the importance of population-level risk assessment of heart disease in light of the growth rate of specific minority populations in the U.S. It describes the population-level dynamics for racial and ethnic minorities: a higher overall prevalence of risk factors for coronary artery disease that are unrecognized and therefore not treated, which increases their likelihood of experiencing adverse outcome and, therefore, potentially higher morbidity and mortality. It discusses the rate of Acute Coronary Syndrome (ACS) in minority communities. Minority patients with ACS are at greater risk of myocardial infarction (MI), rehospitalization, and death from ACS. They also are less likely than non-minority patients to receive potentially beneficial treatments such as angiography or percutaneous coronary intervention. This paper looks at the data surrounding the increased rate of heart disease in racial and ethnic minorities, where the risk is related to the prevalence of comorbidities with hypertension or diabetes mellitus, which, in combination with environmental factors, may largely explain CHF disparity. The conclusion is that it is essential that healthcare providers understand these various communities, including nuances in disease presentation, risk factors, and treatment among different racial and ethnic groups. Awareness of these communities’ attributes, as well as differences in incidence, risk factor burdens, prognosis and treatment are necessary to mitigate racial and ethnic disparities in heart disease.
Collapse
Affiliation(s)
- Garth Graham
- University of Florida Department of Medicine, PO Box 100227, Gainesville, FL 32610 USA.
| |
Collapse
|
3
|
Kumar RS, Douglas PS, Peterson ED, Anstrom KJ, Dai D, Brennan JM, Hui PY, Booth ME, Messenger JC, Shaw RE. Effect of Race and Ethnicity on Outcomes With Drug-Eluting and Bare Metal Stents. Circulation 2013; 127:1395-403. [DOI: 10.1161/circulationaha.113.001437] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background—
Black, Hispanic, and Asian patients have been underrepresented in percutaneous coronary intervention clinical trials; therefore, there are limited data available on outcomes for these race/ethnicity groups.
Methods and Results—
We examined outcomes in 423 965 patients in the National Cardiovascular Data Registry CathPCI Registry database linked to Medicare claims for follow-up. Within each race/ethnicity group, we examined trends in drug-eluting stent (DES) use, 30-month outcomes, and relative outcomes of DES versus bare metal stents. Overall, 390 351 white, 20 191 black, 9342 Hispanic, and 4171 Asian patients > 65 years of age underwent stent implantation from 2004 through 2008 at 940 National Cardiovascular Data Registry participating sites. Trends in adoption of DES were similar across all groups. Relative to whites, black and Hispanic patients undergoing percutaneous coronary intervention had higher long-term risks of death and myocardial infarction (blacks: hazard ratio, 1.28; 95% confidence interval, 1.24–1.32; Hispanics: hazard ratio, 1.15; 95% confidence interval, 1.10–1.21). Long-term outcomes were similar in Asians and whites (hazard ratio, 0.99; 95% confidence interval, 0.92–1.08). Use of DES was associated with better 30-month survival and lower myocardial infarction rates compared with the use of bare metal stents among all race/ethnicity groups except Hispanics, who had similar outcomes with DES or bare metal stents.
Conclusions—
Black and Hispanic patients undergoing percutaneous coronary intervention had worse long-term outcomes relative to white and Asian patients. Compared with bare metal stent use, DES use was generally associated with superior long-term outcomes in all racial and ethnic groups, although these differences were not statistically significant in Hispanic patients.
Collapse
Affiliation(s)
- Robert S. Kumar
- From the Lenox Hill Hospital, New York, NY (R.S.K.); Duke Clinical Research Institute, Durham, NC (P.S.D., E.D.P., K.J.A., D.D., J.M.B., M.E.B.); California Pacific Medical Center, San Francisco (P.Y.M.H., R.E.S.); and Denver VA Medical Center, Denver, CO (J.C.M.)
| | - Pamela S. Douglas
- From the Lenox Hill Hospital, New York, NY (R.S.K.); Duke Clinical Research Institute, Durham, NC (P.S.D., E.D.P., K.J.A., D.D., J.M.B., M.E.B.); California Pacific Medical Center, San Francisco (P.Y.M.H., R.E.S.); and Denver VA Medical Center, Denver, CO (J.C.M.)
| | - Eric D. Peterson
- From the Lenox Hill Hospital, New York, NY (R.S.K.); Duke Clinical Research Institute, Durham, NC (P.S.D., E.D.P., K.J.A., D.D., J.M.B., M.E.B.); California Pacific Medical Center, San Francisco (P.Y.M.H., R.E.S.); and Denver VA Medical Center, Denver, CO (J.C.M.)
| | - Kevin J. Anstrom
- From the Lenox Hill Hospital, New York, NY (R.S.K.); Duke Clinical Research Institute, Durham, NC (P.S.D., E.D.P., K.J.A., D.D., J.M.B., M.E.B.); California Pacific Medical Center, San Francisco (P.Y.M.H., R.E.S.); and Denver VA Medical Center, Denver, CO (J.C.M.)
| | - David Dai
- From the Lenox Hill Hospital, New York, NY (R.S.K.); Duke Clinical Research Institute, Durham, NC (P.S.D., E.D.P., K.J.A., D.D., J.M.B., M.E.B.); California Pacific Medical Center, San Francisco (P.Y.M.H., R.E.S.); and Denver VA Medical Center, Denver, CO (J.C.M.)
| | - J. Matthew Brennan
- From the Lenox Hill Hospital, New York, NY (R.S.K.); Duke Clinical Research Institute, Durham, NC (P.S.D., E.D.P., K.J.A., D.D., J.M.B., M.E.B.); California Pacific Medical Center, San Francisco (P.Y.M.H., R.E.S.); and Denver VA Medical Center, Denver, CO (J.C.M.)
| | - Peter Y.M. Hui
- From the Lenox Hill Hospital, New York, NY (R.S.K.); Duke Clinical Research Institute, Durham, NC (P.S.D., E.D.P., K.J.A., D.D., J.M.B., M.E.B.); California Pacific Medical Center, San Francisco (P.Y.M.H., R.E.S.); and Denver VA Medical Center, Denver, CO (J.C.M.)
| | - Michael E. Booth
- From the Lenox Hill Hospital, New York, NY (R.S.K.); Duke Clinical Research Institute, Durham, NC (P.S.D., E.D.P., K.J.A., D.D., J.M.B., M.E.B.); California Pacific Medical Center, San Francisco (P.Y.M.H., R.E.S.); and Denver VA Medical Center, Denver, CO (J.C.M.)
| | - John C. Messenger
- From the Lenox Hill Hospital, New York, NY (R.S.K.); Duke Clinical Research Institute, Durham, NC (P.S.D., E.D.P., K.J.A., D.D., J.M.B., M.E.B.); California Pacific Medical Center, San Francisco (P.Y.M.H., R.E.S.); and Denver VA Medical Center, Denver, CO (J.C.M.)
| | - Richard E. Shaw
- From the Lenox Hill Hospital, New York, NY (R.S.K.); Duke Clinical Research Institute, Durham, NC (P.S.D., E.D.P., K.J.A., D.D., J.M.B., M.E.B.); California Pacific Medical Center, San Francisco (P.Y.M.H., R.E.S.); and Denver VA Medical Center, Denver, CO (J.C.M.)
| |
Collapse
|